WTO规则与中国生物技术研究的法律保护

WTO Rules and the Improvement of Chinese Insolvent Law

中国生物技术研究取得长足的发展。中国的细胞克隆与胚胎移植研究获得新的突破,但是中国政府对克隆人类研究持反对态度。中国是发展中国家,在生物技术研究、开发诸方面从整体上看还非常落后,必须在WTO法律框架下,加强对生物技术研究的法律保护,用法律形式明确生物技术产权主体,用知识产权手段推动生物技术产业在我国的健康发展。在当前尤其要加强对生物技术的专利保护和基因技术的法律保护,对人类辅助生殖技术实行依法管理,对生物资源进行法制化管理,对违反生物技术法规规定的违法行为依法惩处。

Investing market subject with insolvent responsibility is necessary to build competitive and disciplined market surroundings.Normalizing insolvent procedure and improving insolvent law is necessary to put to practice the non-discrimination treatment of WTO rules.We should hold that not being able to pay the expiry debts is the sole substantive requirement to declare insolvency of enterprises.It should be either the obligation of debtors who can't pay the expiry debts,or the right of the creditors that they apply for enterprises insolvency.We must investigate and ensure the creditors' right,the jurisdiction of insolvent case,and the rational distribution right of insolvent property.Meantime,we must exert insolvent termination procedure and construct the complementary systems of enterprises insolvency.